Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3Sbio Inc. that recently won ...

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at ...

Lai calls for talks with China, says war has no winners China detests Lai as a 'separatist' Lai also unveils plans for sovereign wealth fund President marks one year in office TAIPEI, May 20 ...

Could AI that thinks more like a human be more sustainable than today's LLMs? The AI industry is dominated by large companies with deep pockets and a gargantuan appetite for energy to power their ...

After three years of negotiations sparked by the COVID-19 crisis, countries have adopted the world's first-ever international agreement to better prevent, prepare for, and respond to future pandemics.